

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitut | e for form 1449/ | PTO | • | Complete if Known | | |
|-----------|--------------------|-------------|--------------|------------------------|------------------------|--|
| Outsiller | 0 101 101117 14407 | | | Application Number | 09/501,102-Conf. #3404 | |
| INF | ORMAT | ION D | SCLOSURE | Filing Date | February 9, 2000 | |
| STA | TEMEN | IT BY | APPLICANT | First Named Inventor | Man Sung Co | |
| | | | | Art Unit | 1644 | |
| | (Use as ma | ny sheets a | s necessary) | Examiner Name | P. Gambel | |
| heet | 1 | of | 3 | Attorney Docket Number | WYS-004.01 | |

| | | | U.S. PA | TENT DOCUMENTS | |
|-----------|------|--|------------------|-----------------------------|---|
| Examiner | Cite | Document Number | Publication Date | · Mame of Patentee or | Pages, Columns, Lines, Where Relevant Passages or Relevant |
| Initials* | No.1 | Number-Kind Code ² (if known) | MM-DD-YYYY | opplicant of Cited Document | Figures Appear |
| | AA* | US-5,397,703 | 03-14-1995 | De Boer et al. | |
| | | US-5,562,903 | 10-08-1996 | Qo et al. | |
| | AC* | US-5,622,701 | 04-22-1997/ | Berg | |
| | AD* | US-5,869,050 | 02-09-1999 | de Boer et al. | |
| | AE* | US-5,919,449 | | Dinsmore | |
| | AF* | US-5,977,318 | 11,02-1999 | Linsley et al. | |
| | AG* | US-6,084,067 | 97-04-2000 | Freeman et al. | |
| | AH* | US-6,096,537 | 08-01-2000 | Chappel | / |
| | AJ* | US-6,130,316 | 10-10-2000 | Freeman et al. | |
| | AJ" | US-6,346,248 | 02-12-2002 | De Boer et al. | |
| | AK* | US-6,608,180 | 08-19-2003 | Sharpe et al. | |

| | | FOREIG | SN PATENT | DOCUMENTS | | |
|-----------------------|--------------------------|--|-----------------------------|--|---|----|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | ┲╸ |
| | BA / | WO 94/01547 | 01-20-1994 | | | Г |
| | BP | WO 95/34320 | 12/1995 | | | Г |
| | BC | WO 98/19706 | 05-14-1998 | / | | |
| | BD | WO 00/19706 | 04-06-2000 | | | |

*EXAN INER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filled after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usoto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *5 or Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| | | NON PATENT LITERATURE DOCUMENTS | |
|----------------------|--------------|--|--|
| | | | |
| Examiner Initials | Cite No.1 | The manazing injurnal gonal symposisim catalog atc.) data page(s) volumbe issue hymber(s) hyblisher cib | |
| | CA | Azuma et al., "970 antigen is a second ligand for CTLA 2 and CD28," Nature, 366:76-79 (1993) | |
| | СВ | Berzofsky et al., "Antigen-Antibody Interaction," in Fundamental Immunology, W.E. Paul eds. (NY: Rayen Press), pp. 595-644 (1984) | |
| | cc | Bluestone, J.A., "Costimulation and its role in organ transplantation," Clinical Transplantation, 10:194-109 (1996) | |
| | CD | Chen et al., "Costimulation of Antitumor Immunity by the B7 Counter receptor for the T mphocyte Molecules CD28 and CTLA-4," Cell, 71:1093-1102 (1992) | |
| | CE | Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," The J. of Immunology, 148(4):1149-154 (1992) | |
| | CF | Cromwell et al., Abstract: The Human PBMC-Reconstituted Nod-Scid Mouse as model of Superantigen-Induced Human T Cell Activation, Experimental Biology 98 Meeting, April 22, 1998 | |

| Examiner | • | Data | 1 |
|--------------|---|------------|---|
| [CXalliller] | | Date | 1 |
| 10: | | la | 1 |
| Signature | | Considered | 1 |
| | | | |

NOT CONSIDERED

PHUPGAMBER 5/3/07

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Suit | ostitute for form 1449/PT | 0 | | Complete if Known | | |
|-------|---------------------------|--------------|------------|------------------------|------------------------|--|
| " | | • , | | Application Number | 09/501,102-Conf. #3404 | |
| 11 | NFORMATIC | N DIS | CLOSURE | Filing Date | February 9, 2000 | |
| S | TATEMENT | BY A | PPLICANT | First Named Inventor | Man Sung Co | |
| | | . | | Art Unit | 1644 | |
| | (Use as many | she ets as r | necessary) | Examiner Name | P. Gambel | |
| Sheet | 2 | of | 3 | Attorney Docket Number | WYS-004.01 | |

| C | Daikh et al., "The CD28-B7 costimulatory pathway and its role in autoimmune disease," J. of Leukocyte Biol., 62:156-162 (1997) |
|---|--|
| C | H Damico et al., "Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomolgus Monkeys," Abstract, 17th Annual Scientific Meeting, January 9, 1998 |
| C | B Lymphocytes is the CD86 Differentiation antigen," Blood, 84(5):1402-1407 (1994) |
| C | Fleischer et al., "Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes," Immunology, 89:592-598 (1996) |
| С | Fujihara et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996) |
| С | Immunology, 149(8):2607-2614 (1992) |
| | Goldberg et al., "Pretreatment of renal transplants with anti-CD45 aptibodies: optimization of perfesion technique," Transplant Immunology, 2:27-34 (1994) |
| C | pp. 23-35. |
| C | Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-907 (1993) |
| С | 15619 (1997) |
| | Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126 |
| | R Levitt, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983) |
| | |
| С | Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997) |
| C | Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993) |
| С | NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986) |
| С | Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997) |
| C | Reser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996) |
| C | molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997) |
| C | Z Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999) |
| C | A1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992) |
| С | Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7- Transfected Melanopad Cells," Science, 259:368-369 (1993) |
| | |

| Examiner | Date | |
|------------|----------------|--|
| P-Valimiei | Date | |
| Signature | Canaldonad | |
| Signature | Considered | |

NOT CONSIDERED
PHILIPELMENT 5/2/07

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449/PTO | | | | Complete If Known | | |
|------------------------------|--------------|-------------|-------------|------------------------|------------------------|--|
| - | | | | Application Number | 09/501,102-Conf. #3404 | |
| INF | ORMATI | ON DI | SCLOSURE | Filing Date | February 9, 2000 | |
| STA | ATEMEN' | T BY A | APPLICANT | First Named Inventor | Man Sung Co | |
| | | | | Art Unit | 1644 | |
| | (Use as many | y sheets as | necess ary) | Examiner Name | P. Gambel | |
| Sheet | 3 | of | 3 | Attorney Docket Number | WYS-004.01 | |

| | | |
|------|--|--|
| | onal CD86 (B7-B70) on Cultured Human Langerhans Cells," The exermatelogy, Inc., 106:147-153 (1996) | |
| | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONSIDERED GAMBEL

PITULIA GAMBEL

J3/07

Examiner Date Considered Signature

Applicant's unique citation designation number (optional). Papplicant is to place a check mark here if English language Translation is attached.